Moore KN - Search Results

1

Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).

Buechel ME, Enserro D, Burger RA, Brady MF, Wade K, Secord AA, Nixon AB, Mirniaharikandehei S, Liu H, Zheng B, O'Malley DM, Gray H, Tewari KS, Mannel RS, Birrer MJ, Moore KN. Buechel ME, et al. Among authors: moore kn. Gynecol Oncol. 2021 May;161(2):382-388. doi: 10.1016/j.ygyno.2021.02.032. Epub 2021 Mar 10. Gynecol Oncol. 2021. PMID: 33712274 Free PMC article. Clinical Trial.

2

Can frequency and severity of symptoms predict the presence of ovarian cancer?

Moore KN, Walker JL. Moore KN, et al. Nat Clin Pract Oncol. 2004 Dec;1(2):72-3. doi: 10.1038/ncponc0040. Nat Clin Pract Oncol. 2004. PMID: 16264821 No abstract available.

3

Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma.

Moore KN, Gold MA, McMeekin DS, Zorn KK. Moore KN, et al. Gynecol Oncol. 2007 Sep;106(3):498-501. doi: 10.1016/j.ygyno.2007.04.030. Epub 2007 Jun 11. Gynecol Oncol. 2007. PMID: 17561235

4

Pathologic findings and outcomes for octogenarians presenting with uterine malignancy.

Moore KN, Lanneau GS, Smith C, Lanneau M, Walker JL, Gold MA, Scott McMeekin D. Moore KN, et al. Gynecol Oncol. 2007 Sep;106(3):572-8. doi: 10.1016/j.ygyno.2007.05.028. Epub 2007 Jul 5. Gynecol Oncol. 2007. PMID: 17618678

5

Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.

Landrum LM, Gold MA, Moore KN, Myers TK, McMeekin DS, Walker JL. Landrum LM, et al. Among authors: moore kn. Gynecol Oncol. 2008 Feb;108(2):342-7. doi: 10.1016/j.ygyno.2007.10.004. Epub 2007 Nov 7. Gynecol Oncol. 2008. PMID: 17988721

6

Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.

Moore KN, Moxley KM, Fader AN, Axtell AE, Rocconi RP, Abaid LN, Cass IA, Rose PG, Leath CA 3rd, Rutledge T, Blankenship D, Gold MA. Moore KN, et al. Gynecol Oncol. 2007 Dec;107(3):398-403. doi: 10.1016/j.ygyno.2007.09.027. Epub 2007 Nov 7. Gynecol Oncol. 2007. PMID: 17997146

7

Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes.

Moore KN, Gold MA, McMeekin DS, Walker JL, Rutledge T, Zorn KK. Moore KN, et al. Gynecol Oncol. 2008 Mar;108(3):466-71. doi: 10.1016/j.ygyno.2007.11.043. Epub 2008 Jan 14. Gynecol Oncol. 2008. PMID: 18191994

8

Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?

Moore KN, Reid MS, Fong DN, Myers TK, Landrum LM, Moxley KM, Walker JL, McMeekin DS, Mannel RS. Moore KN, et al. Gynecol Oncol. 2008 Aug;110(2):133-9. doi: 10.1016/j.ygyno.2008.03.008. Epub 2008 May 20. Gynecol Oncol. 2008. PMID: 18495221

9

Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.

Landrum LM, Moore KN, Myers TK, Lanneau GS Jr, McMeekin DS, Walker JL, Gold MA. Landrum LM, et al. Among authors: moore kn. Gynecol Oncol. 2009 Feb;112(2):337-41. doi: 10.1016/j.ygyno.2008.10.009. Epub 2008 Nov 28. Gynecol Oncol. 2009. PMID: 19041126

10

Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.

Fader AN, Nagel C, Axtell AE, Zanotti KM, Kelley JL, Moore KN, Secord AA, Walsh CS, Huh WK, Gehrig PA, Gibbons H, Rose PG, Havrilesky LJ, Tuller E, Drake RD, Bottsford-Miller J, O'Malley DM; UPSC Consortium. Fader AN, et al. Among authors: moore kn. Gynecol Oncol. 2009 Mar;112(3):558-62. doi: 10.1016/j.ygyno.2008.11.016. Epub 2009 Jan 1. Gynecol Oncol. 2009. PMID: 19118888

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

331 results

Search Page